Neuronetics, Inc. - Common Stock (STIM)

Neuronetics (STIM) reported mixed Q2 2025 results, beating revenue estimates but posting a wider-than-expected loss, causing a 9% pre-market drop. Greenbrook clinics hit record revenue.

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and positive EBITDA by 2025. Neuronetics to hold 57% ownership.

STIM stock results show that Neuronetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

These neurotech stocks stand at the cutting edge of healthcare, but early entrants in new fields tend to be long-term winners.

Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning!

STIM stock results show that Neuronetics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.